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Symptomatic adrenal insuYciency during inhaled
corticosteroid treatment
L Patel, J K Wales, M S Kibirige, A A Massarano, J M Couriel, P E Clayton
Abstract
Symptomatic adrenal insuYciency, pre-
senting as hypoglycaemia or poor weight
gain, may occur on withdrawal of cortico-
steroid treatment but has not previously
been reported during inhaled cortico-
steroid treatment. This case series illus-
trates the occurence of clinically
significant adrenal insuYciency in asth-
matic children while patients were on
inhaled corticosteroid treatment and the
unexpected modes of presentation. Gen-
eral practitioners and paediatricians need
to be aware that this unusual but acute
serious complication may occur in pa-
tients treated with inhaled cortico-
steroids.
(Arch Dis Child 2001;85:330–334)
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Impaired linear growth and hypothalamic–
pituitary–adrenal (HPA) suppression on bio-
chemical testing are recognised systemic eVects
of inhaled corticosteroids (ICS) in doses <400
µg/day.1 2 In addition, a Cushingoid appearance
with central obesity and fatigue have been
reported with high doses.3 4 Features of adrenal
insuYciency, such as hypoglycaemia and
weight loss, may occur on withdrawal of exog-
enous ICS treatment.5 Despite HPA suppres-
sion, symptomatic adrenal insuYciency does
not occur during treatment with pharmaco-
logical doses (exceeding physiological cortisol
secretion) and has not previously been re-
ported during treatment with subpharmaco-
logical doses as delivered by the inhaled route.
The aim of this case series is to describe the
occurence of clinically significant adrenal
insuYciency in association with HPA suppres-
sion in asthmatic children while patients were
on ICS treatment, and the unexpected modes
of presentation.
Case series
CLINICAL FEATURES AT PRESENTATION
Between January 1997 and March 1999, eight
children (five boys, three girls; median age 6.9
years, range 4.5–10.0) with varied presenta-
tions came to the attention of specialists at
three paediatric endocrine services in the north
of England. They were identified on clinical
assessment and biochemical testing to have
adrenal insuYciency and HPA suppression.
Table 1 summarises their clinical features at
presentation and results of biochemical tests.
All had mild to moderately severe asthma, were
managed by general practitioners or general
paediatricians, had responded clinically to ICS
treatment, and were deemed to be compliant
with their treatment. Case 4 had coexisting
allergic rhinitis and had received budesonide
nasal spray 400 µg/day for six months. The
remaining cases had not received cortico-
steroids by any other route in the six months
prior to presentation. None had received
prolonged courses of systemic corticosteroids
at any time. No patient had hyperpigmenta-
tion.
Cases 1 and 2 presented acutely with
hypoglycaemia while receiving treatment with
inhaled fluticasone. Their treatment had not
been suddenly withdrawn prior to presenta-
tion. Neither patient had an acute intercurrent
illness nor other stressful event at the time of
presentation. Metabolic and other endocrine
causes of hypoglycaemia were excluded by bio-
chemical investigations (normal values of urine
organic acid profile and blood acyl carnitine,
insulin and C peptide at the time of hypogly-
caemia, growth hormone, thyroxine, and TSH)
and subsequent progress.
The presentation in the remaining patients
was insidious. Notable features in cases 3–6
were poor weight gain while patients were
receiving ICS treatment. This was associated
with poor growth in height in cases 4–6. These
features were not caused by uncontrolled
asthma, coexisting systemic disease, or other
endocrine abnormality. In addition to poor
growth in height, case 7 had hirsutism with no
other endocrine abnormality and case 8 had
recurrent headaches but no head and neck or
neurological abnormalities.
INVESTIGATION RESULTS AT PRESENTATION
HPA suppression was identified by: (1) low
basal plasma cortisol (all cases); and (2)
impaired response to standard dose ACTH
(Synacthen) test (cases 1–5, 8) or low 24 hour
urine cortisol metabolites (cases 6, 7) (table 1).
The pituitary–adrenal axis was unresponsive to
stimulation with corticotrophin releasing factor
(CRF) at presentation in cases 1, 3, and 4
(plasma cortisol <20 nmol/l and plasma
Arch Dis Child 2001;85:330–334330
Department of Child
Health, University of
Manchester, Booth
Hall Childrens
Hospital, Manchester
M9 7AA, UK
L Patel
J M Couriel
P E Clayton
Department of Child
Health, University of
SheYeld, UK
J K Wales
South Cleveland
Hospital,
Middlesbrough, UK
M S Kibirige
Tameside General
Hospital, Lancashire,
UK
A A Massarano
Correspondence to:
Dr Patel
lp@man.ac.uk
Accepted 14 June 2001
www.archdischild.com
ACTH <5 pmol/l at all time points). In the
patients who had ultrasound examination of
the abdomen, the adrenal glands appeared
normal in cases 1, 3, and 7 but could not be
identified in case 4. Autoantibody screen was
negative in all.
MANAGEMENT AND PROGRESS
The dose of ICS at presentation did not exceed
that recommended in step 3 of the British
Thoracic Society Guidelines in seven of these
eight cases (case 8 was the exception).6
However, only two patients (cases 6 and 7)
were receiving medication within the licenced
prescription (beclomethasone 400 µg/day, fluti-
casone 200 µg/day, and budesonide 800
µg/day). Case 2 had received fluticasone 1500
µg/day for four weeks, 1000 µg/day for four
weeks, and 500 µg/day for eight weeks prior to
presentation. We are not aware of other
patients receiving higher doses of ICS than
those mentioned in table 1.
The management of adrenal insuYciency
included: (1) informing parents about a poten-
tial adrenal crisis, management of acute stress-
ful events, and precautions necessary to
prevent this emergency; and (2) training
parents to manage an acute adrenal crisis and
providing open access to the hospital accident
and emergency department. Daily hydrocorti-
sone replacement (physiological dose 12 mg/
m2/day orally, with two thirds of the dose in the
morning and one third in the evening) was
indicated in patients who presented with
hypoglycaemia (cases 1 and 2) and those with
no adrenocortical reserve (cases 3 and 4, and
case 7 for 18 months). In the remaining
patients, hydrocortisone replacement was re-
served for acute stressful events. Patients were
reviewed at four to eight weekly intervals and
an attempt was made to gradually reduce the
dose of ICS while simultaneously maintaining
adequate control of asthma symptoms. Bio-
chemical tests of HPA axis function were
repeated after successful reduction in dose of
ICS or gradual withdrawal of treatment. Any
ICS treatment and hydrocortisone replace-
ment were withheld for 24 hours prior to test-
ing.
Normal ACTH test responses and 24 hour
urine cortisol metabolites were obtained in
four cases after: (1) gradual withdrawal of ICS
with salmeterol (case 7 over 18 months when
hydrocortisone was also discontinued) or with-
out salmeterol (case 8 over three months); and
(2) change in ICS preparation without salm-
eterol (case 5 from beclomethasone 600 µg/day
to budesonide 200 µg/day over six months) or
with addition of salmeterol (case 6 from
budesonide 400 µg/day to fluticasone 250
µg/day over three months). Fluticasone was
discontinued in case 3 after two years.
Subsequent biochemical tests showed some
recovery of HPA function (Synacthen test peak
Table 1 Clinical features of adrenal insuYciency in eight patients identified to have hypothalamic–pituitary–adrenal suppression during inhaled
corticosteroid treatment
Case, sex
Clinical features at presentation
(age) Age in y
Height in cm
(SDS)
Weight in kg
(SDS)
HPA function at presentation
(plasma cortisol in nmol/l)
Inhaled corticosteroid, daily dose
(dose/m2/day) device; duration
1, M Acute: unconscious, plasma
glucose 0.9 mmol/l (4.5 y)
4.5 98.2 (−2.0) 14.1 (−2.1) Plasma cortisol 100 at 0800*,
SDST peak 200
Fluticasone 500 µg/day (780
µg/m2/day) volumatic; 6 mth
6.3 108.5 (−1.8) 18.6 (−1.1)
2, F Acute: drowsy, disoriented and
headache for 24 h, plasma
glucose 0.7 mmol/l. Also had
poor growth in height and
weight for 12 mth (5.8 y)
4.8 104.0 (−0.7) 17.0 (−0.3) Plasma cortisol 30 at 0900*,
SDST peak 30
Budesonide 400 µg/day (570
µg/m2/day) nebuhaler; 15 mth,
followed by fluticasone 500 µg/day
(705 µg/m2/day) volumatic; 4 mth
5.8 106.0 (−1.7) 17.0 (−1.2)
7.0 119.7 (−0.3) 24.4 (0.4)
3, M Insidious: weight loss and
listlessness for 3 mth (4.5 y)
4.2 97.8 (−1.5) 15.1 (−1.0) Plasma cortisol 100 at 0830*,
SDST peak 20
Fluticasone 500 µg/day (770
µg/m2/day) volumatic; 6 mth
4.7 101.1 (−1.5) 14.9 (−1.7)
7.0 118.5 (−0.6) 22.5 (−0.1)
4, M Insidious: poor growth in height
and weight for 2 y (8.0 y)
5.8 109.0 (−1.1) 18.5 (−0.7) Plasma cortisol <20 at 0900*,
SDST peak <20
Fluticasone 500 µg/day (610
µg/m2/day) volumatic; 4.5 y
8.0 114.6 (−2.4) 21.2 (−1.4)
9.7 126.7 (−1.6) 30.9 (0.1)
5, M Insidious: poor growth in height
and weight for 12 mth (10.0 y)
9.0 121.9 (−2.0) 22.1 (−1.9) Plasma cortisol 90 at 0900*,
SDST peak 300
Beclomethasone dipropionate 600
µg/day (690 µg/m2/day) dischaler; 3 y
10.0 125.0 (−2.2) 23.3 (−2.2)
11.2 130.6 (−2.0) 26.9 (−1.8)
6, F Insidious: poor growth in height
and weight for 2 y (9.8 y)
6.1 110.7 (−1.0) 17.1 (−1.4) Plasma cortisol 162 at 0900*;
24 h urine cortisol
metabolites low† (THC 380
µg, THE 70 µg)
Budesonide 400 µg/day (505
µg/m2/day) nebuhaler; 5 y
9.3 120.0 (−2.4) 18.8 (−3.2)
11.3 137.0 (−1.2) 27.6 (−1.7)
7, M Insidious: poor growth in height
and hirsutism for 6 mth (5.6 y)
4.8 99.6 (−1.9) 16.0 (−1.1) Plasma cortisol <20 and 30 at
0900*; 24 h urine cortisol
metabolites undetectable†
Budesonide 400 µg/day (595
µg/m2/day) nebuhaler; 12 mth
5.6 101.5 (−2.5) 17.1 (−1.2)
6.7 111.5 (−1.6) 19.6 (−1.0)
8, F Insidious: poor growth in height
and headaches for 12 mth (8.4
y)
7.2 116.0 (−1.2) 21.0 (−0.7) Plasma cortisol 33 at 0900*,
SDST peak 325
Fluticasone 1000 µg/day (1136
µg/m2/day) volumatic; 18 mth
8.5 119.5 (−1.9) 23.5 (−0.8)
10.1 128.0 (−1.6) 33.9 (0.2)
Rows in bold represent measurements after the diagnosis of adrenal insuYciency.
*0700–0900 plasma cortisol (normal range 250–700 nmol/l).
†24 h urine cortisol metabolites: THC, tetrahydrocortisol (normal range 500–1300 µg); THE, tetrahydrocortisone (normal range 200–550 µg).
SDST, standard dose Synacthen (ACTH) test (criterion for normal response is peak plasma cortisol >500 nmol/l).
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plasma cortisol 400 nmol/l) and his dose of oral
hydrocortisone is currently being reduced. The
remaining cases have continued to require oral
hydrocortisone replacement for over three
years despite some alterations to their ICS
treatment and salmeterol (case 1 from flutica-
sone 500 µg/day to budesonide 300 µg/day;
case 2 from fluticasone 500 µg/day to budeso-
nide 400 µg/day; case 4 from fluticasone 500
µg/day to budesonide 800 µg/day).
Catch up growth in weight and height (table
2) was observed in all patients: with hydrocor-
tisone replacement (cases 1–4, 7), ICS with-
drawal (cases 3, 7, and 8) and change in ICS
preparation (cases 5 and 6).
Discussion
As exogenous corticosteroids cause greatest
suppression of ACTH secretion, it may be dif-
ficult to diVerentiate from isolated ACTH or
CRF deficiency, particularly when the cortico-
steroid dose is in the normal range. Not only
are the latter extremely uncommon, but the
time course of events in relation to ICS
treatment in our patients makes isolated
ACTH or CRF deficiency less likely. The
absence of troublesome asthma symptoms
when growth was impaired and subsequent
catch up growth after the diagnosis and
management of adrenal insuYciency excludes
uncontrolled asthma as an explanation for the
poor growth and is highly suggestive of reversal
of adrenal insuYciency induced by ICS
treatment. Impaired growth in height is a
feature of Cushing’s syndrome secondary to
excess exogenous ICS,3 4 a recognised systemic
eVect of conventional doses of ICS1 2 and also a
sign of adrenal insuYciency. However, the key
to diVerentiation is increased or normal weight
gain in the former and poor weight gain/weight
loss in adrenal insuYciency.
This case series highlights an unrecognised
paradoxical complication during ICS treat-
ment with doses within current recommended
guidelines.6 All patients were symptomatic but
the presenting features were varied and unex-
pected: features of adrenal insuYciency (poor
weight gain, hypoglycaemia) predominated
over well known peripheral eVects of excess
exogenous corticosteroids (iatrogenic Cush-
ing’s syndrome). Our observations and the
large reported range of eVects on linear growth
and HPA function,1 7 and occurrence of
adverse eVects with doses of ICS normally
considered to be safe8 9 illustrate variations in
individual sensitivity to corticosteroids. In
addition, corticosteroid sensitivity is also likely
to vary between diVerent target tissues, and a
lack of correspondence between diVerent
corticosteroid eVects has been reported in
healthy and non-asthmatic adults.10–12 DiVeren-
tial tissue sensitivity has also been proposed as
an explanation for those patients with asthma
who fail to respond to corticosteroid treatment
but who have systemic eVects.13 In our cases, it
is likely that the systemic bioavailability of ICS
was suYcient to suppress the HPA axis but not
adequate enough to provide physiological
corticosteroid replacement and thus prevent
symptoms of hypoadrenalism. This, along with
diVerential tissue sensitivity explains the pre-
dominant features of adrenal insuYciency,
including hypoglycaemia, listlessness, and poor
weight gain with poor growth in height.
Adrenal insuYciency, irrespective of cause,
is one of the acute life threatening emergencies
in paediatric practice. General practitioners
and paediatricians need to be aware that it may
occur in patients treated with ICS and of the
unusual modes of presentation to provide
timely management. Although the daily dose
of ICS for seven of the eight cases might not be
considered excessive, all patients were small
(weight and height SD scores <0) and
consequently their dose per m2 body surface
area was relatively higher. Evidence based
guidelines with doses of ICS recommended
according to body surface area are needed.
The diVering potencies of the various ICS
preparations, including the widely accepted
2:1 ratio between fluticasone and other ICS
preparations, also needs to be taken into
account. We emphasise that the distribution of
the ICS preparations used in our small series
should not be extrapolated to that used in the
general population. Furthermore, as our
patients had well controlled asthma, an
attempt should have been made to reduce their
dose of ICS treatment during the period
before presentation.6 Failure to do so was a
possible risk factor for adrenal suppression.
Alternative treatments such as salmeterol and
leukotriene receptor antagonists may have a
role in patients who do not respond to
conventional doses of ICS. Although all our
patients were deemed to be compliant with
their treatment, failure to take treatment and
sudden withdrawal are additional risk factors
for acute adrenal crisis.5
When using ICS in the management of
asthma, there is a clear need to be ever
cautious, as a few children as outlined in this
series can get serious systemic eVects, such as
hypoglycaemia secondary to adrenal insuY-
ciency, that cannot readily be predicted. As
growth and weight failure was an important
feature of our cases, we must emphasise the
importance of growth monitoring for all
children on ICS. If growth failure is detected,
adrenal insuYciency should be considered and
investigated with dynamic tests of adrenal
function.
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(p with t test) (p = 0.01) (p = 0.003)
Mean (SD) change in weight SDS −0.7 (0.6) 1.1 (0.6)
(p with t test) (p = 0.03) (p = 0.001)
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Commentary
When inhaled corticosteroid (ICS) therapy was
introduced to clinical practice, it was at a time
when the therapeutic options for asthma
prophylaxis were limited to theophylline and
sodium cromoglycate, and many asthmatic
children were still on regular oral cortico-
steroids. Early searches for side eVects from
ICS gave uniformly reassuring results, and the
new treatment was welcomed as a safe and
eVective alternative to1 and substitute for2 oral
prednisolone, even when high dose ICS was
necessary.3 The adrenal atrophy reported at
autopsy in asthmatic children who had died
while on ICS4 was widely attributed to
concomitant treatment with systemic cortico-
steroids, and the report was discounted.
This honeymoon period was not to last for
long. The first side eVect to be noted was
oropharyngeal moniliasis, and since then ICS
therapy has been shown to be capable of
producing most of the features of glucocorti-
coid excess. In a recent review of 163 consecu-
tive children aged 9 years of age or above
admitted with intractable asthma to the
National Jewish Hospital in Denver, Covar and
colleagues5 found that even in the half who
were not already on regular systemic cortico-
steroids, but were on high dose ICS, there was
a high prevalence of corticosteroid side eVects,
including hypertension, Cushingoid features,
adrenal suppression, myopathy, osteopenia,
growth suppression, obesity, hypercholesterol-
aemia, cataracts, and growth retardation.
Adverse eVects on carbohydrate metabolism
have been noted in some studies, with raising of
the insulin:glucose ratio on high dose ICS,6 and
a slight decline in oral glucose tolerance.7 In
contrast, it has also been reported that the
reduction of stress may have beneficial eVects
on carbohydrate metabolism when asthma is
controlled by ICS.8
A common feature in reports from the mid-
1980s onwards has been dose related adrenal
suppression,9–13 a side eVect that has generally
been regarded as benign, representing nothing
more than a physiological response to exog-
enous corticosteroid. Clinical symptoms of
hypoadrenalism have not appeared to be a
problem. It is therefore surprising that after
more than a quarter of a century’s relatively
trouble free use of ICS, Patel et al should report
no fewer than eight cases of clinically signifi-
cant adrenal suppression in children on ICS
therapy.
In two cases there was acute hypoglycaemia,
not apparently caused by the sudden with-
drawal of ICS, though this is the explanation
that springs most readily to mind. These two
cases are particularly worrying, suggesting that
acute adrenal insuYciency can occur even
when the child is still taking the exogenous
corticosteroid that caused the adrenal insuY-
ciency in the first place. Clearly, paediatricians
will have to be vigilant in investigating
asthmatic children with disturbed conscious-
ness, unusual behaviour, or autonomic symp-
toms suggestive of hypoglycaemia. In addition,
given the lingering suspicion that the ICS
treatment must have been discontinuous (if not
indeed discontinued), prescribers of ICS must
emphasise the importance of compliance, and
ensure that when treatment is successful, it is
stepped down gradually rather than stopped
suddenly.
The other cases presented insidiously, five
with impaired growth over periods ranging
from six months to two years. In only one did
the ICS dose exceed current recommenda-
tions.
The authors are quite clear that the asthma
was well controlled in these children, and this
might have played a part in ensuring the
systemic absorption of what are unremarkable
doses of ICS. The systemic eVects of budeso-
nide and fluticasone reflect mainly lung
bioavailability,14 and it has been shown that the
systemic bioavailability of ICS is greater in
subjects with healthy airways than in asthmat-
ics.15 16 Thus, if in these cases the doses of ICS
were greater than was strictly necessary,
enhanced systemic absorption might have
ensued, although a logical extension of this
argument would be that perfect control is an
undesirable end point for ICS therapy.
Perhaps we should have advised against the
inclusion of case 7, whose presenting features
included hirsutism, hardly a feature of simple
adrenal suppression. His body mass index was
rather better than in the others, and he may
well have had some other endocrine abnormal-
ity. However, none was found and on balance
we decided that all eight cases should be
included.
We can only guess at the prevalence of clini-
cally significant adrenal suppression in children
on ICS, but clearly we can no longer claim that
it is non-existent. Nor can we be sure that the
distribution of the individual corticosteroid
molecules used by these children is anything
other than a chance phenomenon. The authors
are rightly cautious in refusing to comment.
But it can hardly pass unnoticed that only one
of these eight children was on beclomethasone,
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whereas the others were on what are sometimes
described as second or even third generation
ICS. Beclomethasone was the first and is still
the most widely used ICS in the UK. In
England in 1998, 8.43 million NHS prescrip-
tions were filled for beclomethasone, compared
to only 1.88 million for budesonide and 1.54
million for fluticasone.17 We too are cautious in
our interpretation of these proportions, but
await with interest further reports of ICS
related adrenal suppression.
So, what are the conclusions to be drawn
from this report? In our current state of knowl-
edge, it would be quite wrong to suggest a
major change in established practice. ICS
treatment has been of immense value to
literally millions of children, and other anti-
asthma therapy is best regarded as steroid
sparing18 rather than a true alternative to ICS.
Nevertheless, we should review our practice
and pay more attention to existing recommen-
dations on the importance of stepping down as
well as stepping up ICS,19 and, as ever, we must
be constantly vigilant for unforeseen side
eVects of even the best established drugs.
Whatever else we do, we must not panic and
endanger the lives and wellbeing of the count-
less children whose respiratory and endocrine
systems co-exist happily on ICS.
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